After China Trodelvy OK, Everest Medicines CEO resigns and the hunt is on for his replacement
Shanghai-based Everest Medicines CEO has hit the company’s exit door.
Kerry Blanchard has resigned as the CEO and as a member of the board of directors, effective immediately, Everest announced Friday. After spending nearly 17 years at Eli Lilly where he rose to the rank of VP, Blanchard spent three years as a top executive for other pharma companies in China, including a year-long stint at Innovent Biologics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.